(STI) Solidion Technology - Ratings and Ratios
Anode, All-Solid-State, Lithium-Sulfur, Module
Dividends
Currently no dividends paid| Risk via 10d forecast | |
|---|---|
| Volatility | 69.2% |
| Value at Risk 5%th | 93.2% |
| Relative Tail Risk | -18.19% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.66 |
| Alpha | -100.74 |
| CAGR/Max DD | -0.76 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.232 |
| Beta | 3.087 |
| Beta Downside | 1.789 |
| Drawdowns 3y | |
|---|---|
| Max DD | 99.48% |
| Mean DD | 60.79% |
| Median DD | 94.72% |
Description: STI Solidion Technology October 20, 2025
Solidion Technology, Inc. (NASDAQ: STI) develops and commercializes next-generation battery materials and cell technologies, including advanced silicon-rich anodes, all-solid-state lithium-ion cells, anode-less lithium-metal cells, and lithium-sulfur cells. The firm operates as a subsidiary of Global Graphene Group and is headquartered in Dallas, Texas.
STI trades as a common stock under the ticker “STI,” is incorporated in the United States, and is classified in the GICS sub-industry “Electrical Components & Equipment.”
Key industry context: the global solid-state battery market is projected to grow at a CAGR of roughly 30 % from 2024-2030, driven by rising EV adoption and government incentives for higher-energy-density storage. Solidion disclosed a $55 million Series A financing round in 2023 and announced a pilot production line capable of 100 kWh per month, positioning it to capture early-stage demand. However, the company’s commercial scale-up risk remains high, as demonstrated-volume manufacturing for solid-state chemistries is still nascent and capital-intensive.
For a deeper quantitative assessment of STI’s valuation relative to peers, the ValueRay platform offers a data-rich dashboard worth exploring.
Piotroski VR‑10 (Strict, 0-10) 2.0
| Net Income (-8.56m TTM) > 0 and > 6% of Revenue (6% = 24.5k TTM) |
| FCFTA -1.07 (>2.0%) and ΔFCFTA 0.04pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue -5266 % (prev -428.8k%; Δ 423.5kpp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -1.03 (>3.0%) and CFO -5.31m > Net Income -8.56m (YES >=105%, WARN >=100%) |
| Net Debt (1.74m) to EBITDA (3.53m) ratio: 0.49 <= 3.0 (WARN <= 3.5) |
| Current Ratio 0.04 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (3.08m) change vs 12m ago 54.66% (target <= -2.0% for YES) |
| Gross Margin 47.66% (prev -7312 %; Δ 7360 pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 7.19% (prev 0.09%; Δ 7.10pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 1.39 (EBITDA TTM 3.53m / Interest Expense TTM 652.4k) >= 6 (WARN >= 3) |
ValueRay F-Score (Strict, 0-100) 34.91
| 1. Piotroski 2.0pt |
| 2. FCF Yield -6.85% |
| 3. FCF Margin data missing |
| 4. Debt/Equity -0.11 |
| 5. Debt/Ebitda 0.49 |
| 6. ROIC - WACC (= -23.57)% |
| 7. RoE 51.58% |
| 8. Rev. Trend 31.37% |
| 9. EPS Trend -16.64% |
What is the price of STI shares?
Over the past week, the price has changed by -10.85%, over one month by -30.80%, over three months by +41.67% and over the past year by -63.24%.
Is STI a buy, sell or hold?
What are the forecasts/targets for the STI price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 71.5 | 855.9% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 4.8 | -36.1% |
STI Fundamental Data Overview December 02, 2025
P/S = 5932.5645
P/B = 663973.3535
Beta = 0.625
Revenue TTM = 408.0k USD
EBIT TTM = 906.0k USD
EBITDA TTM = 3.53m USD
Long Term Debt = unknown (0.0)
Short Term Debt = 1.91m USD (from shortTermDebt, last quarter)
Debt = 1.91m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.74m USD (from netDebt column, last quarter)
Enterprise Value = 80.9m USD (79.2m + Debt 1.91m - CCE 160.5k)
Interest Coverage Ratio = 1.39 (Ebit TTM 906.0k / Interest Expense TTM 652.4k)
FCF Yield = -6.85% (FCF TTM -5.55m / Enterprise Value 80.9m)
FCF Margin = -1359 % (FCF TTM -5.55m / Revenue TTM 408.0k)
Net Margin = -2097 % (Net Income TTM -8.56m / Revenue TTM 408.0k)
Gross Margin = 47.66% ((Revenue TTM 408.0k - Cost of Revenue TTM 213.5k) / Revenue TTM)
Gross Margin QoQ = -678.4% (prev -1670 %)
Tobins Q-Ratio = 15.67 (Enterprise Value 80.9m / Total Assets 5.17m)
Interest Expense / Debt = 5.90% (Interest Expense 112.4k / Debt 1.91m)
Taxrate = -0.0% (0.0 / -4.09m)
NOPAT = 906.0k (EBIT 906.0k * (1 - -0.00%))
Current Ratio = 0.04 (Total Current Assets 1.01m / Total Current Liabilities 22.5m)
Debt / Equity = -0.11 (negative equity) (Debt 1.91m / totalStockholderEquity, last quarter -17.3m)
Debt / EBITDA = 0.49 (Net Debt 1.74m / EBITDA 3.53m)
Debt / FCF = -0.31 (negative FCF - burning cash) (Net Debt 1.74m / FCF TTM -5.55m)
Total Stockholder Equity = -16.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -165.6% (out of range, set to none)
RoE = 51.58% (negative equity) (Net Income TTM -8.56m / Total Stockholder Equity -16.6m)
RoCE = -5.46% (negative capital employed) (EBIT 906.0k / Capital Employed (Equity -16.6m + L.T.Debt 0.0))
RoIC = -6.45% (NOPAT 906.0k / Invested Capital -14.1m)
WACC = 17.12% (E(79.2m)/V(81.1m) * Re(17.39%) + D(1.91m)/V(81.1m) * Rd(5.90%) * (1-Tc(-0.0)))
Discount Rate = 17.39% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 44.95%
Fair Price DCF = unknown (Cash Flow -5.55m)
EPS Correlation: -16.64 | EPS CAGR: 0.01% | SUE: N/A | # QB: 0
Revenue Correlation: 31.37 | Revenue CAGR: 295.8% | SUE: N/A | # QB: 0
Additional Sources for STI Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle